SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule, the company’s oral delivery platform, at ObesityWeek® 2025 taking place both virtually and in-person on November 4-7,... Read More

SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Abraham (“Abe”) Bassan and Vasudev Bailey, Ph.D., to its Board of Directors. In conjunction with the new appointments, Andrew Farquharson and Maulik Nanavaty have... Read More

Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir Imran Each of Samsara and Anomaly has the right to designate one member of the Company’s board of directors SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a... Read More

Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir Imran At the closing of the financing, each of Samsara and Anomaly will have the right to designate one member of the Company’s board of directors SAN JOSE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani... Read More

Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit royalties on product sales for the first license agreement Chugai has the option to extend its rights to partner with Rani on up to 5 additional drug targets at similar deal terms bringing the total potential deal value to over $1... Read More

Announced strategic research collaboration with Chugai for two undisclosed molecules Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to subcutaneous delivery at ENDO 2025 Phase 1 study for RT-114 for the treatment of obesity expected to initiate in the second half of 2025 Announced a warrant inducement transaction with... Read More

SAN JOSE, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 4,354,000 shares of Rani Therapeutics’ Class A common stock at... Read More

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA. Details of the... Read More

Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against undisclosed targets SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company has entered into a Research... Read More

Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 Phase 1 study for RT-114 for the treatment of obesity expected to initiate in mid-2025 Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule SAN JOSE, Calif., May 13, 2025... Read More

Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule Preclinical data of four incretin-based molecules underscores the RaniPill® platform's potential to facilitate the oral delivery of a... Read More

RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence Both groups demonstrated comparable weight loss with less variability observed with RT-114 compared to subcutaneous PG-102 Phase 1 clinical... Read More

SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2024 and provide a business update on Monday, March 31, 2025 after the close of... Read More

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration RT-116 was well tolerated with no serious adverse events Data adds to growing body of evidence of the RaniPill ® platform’s potential to enable oral delivery of... Read More

Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 Announced new preclinical pharmacokinetic data supporting transenteric delivery of GLP-1 incretin triagonist Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 SAN JOSE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics... Read More

SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in three upcoming conferences. These conferences include: UBS Global Healthcare Conference Location: Terranea Resort, Rancho Palos... Read More

Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and bioavailability comparable to subcutaneous injection New pharmacokinetic data provides further evidence of the RaniPill platform’s potential to enable oral delivery of... Read More

SAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,000,000 shares of Rani Therapeutics’ Class A common stock... Read More

SAN JOSE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on... Read More

SAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in September 2024. These conferences include: H.C. Wainwright 26 th Annual Global Investment Conference Location:... Read More

Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity Phase 1 study for RT-114 expected to initiate in 2025 Completed equity offering with gross proceeds of approximately $10.0 million Presented clinical and preclinical data on oral delivery of an ustekinumab biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024 SAN JOSE, Calif., Aug. 06, 2024... Read More

SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in August 2024. These conferences include: BTIG Virtual Biotechnology Conference Location: Virtual Date: Monday,... Read More

SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 2,800,000 shares of Rani Therapeutics’ Class A common stock... Read More

New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection Rani and ProGen to share responsibilities for the development and commercialization of RT-114, including a 50/50 cost and revenue share arrangement Rani to host conference... Read More

SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc . (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These conferences include: H.C. Wainwright 2nd Annual BioConnect Investor Conference Location: The... Read More

SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill ® capsule, the company’s oral delivery platform, at Digestive Disease Week ® (DDW) taking place both virtually and... Read More

Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 RaniPill HC to be ready for potential Phase 1 clinical trials in the second half of 2024 SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a... Read More

Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist Cash runway extended into 2025 Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq:... Read More

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading.... Read More

RT-111 achieved high bioavailability in humans RT-111 was well-tolerated, with no serious adverse events Celltrion has right of first negotiation to acquire worldwide rights to RT-111 following a Phase 1 clinical trial that meets its primary endpoints Rani has now successfully completed three Phase 1 trials using RaniPill ®... Read More

Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study Preclinical data support the potential for the RaniPill platform to enable oral delivery of multiple obesity treatments SAN JOSE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc.... Read More

Cash runway extended into 2025 Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations Initiated Phase 1 clinical trial of RT-111, a RaniPill GO containing ustekinumab biosimilar CT-P43, with topline results expected in 1Q 2024 Initiation of Phase 2 clinical trial of... Read More

Cash runway extended into 2025 Cash runway expected to extend beyond topline results from Phase 2 trial for RT-102, topline results from Phase 1 trial for RT-111, and development of RaniPill® HC to be Phase 1 ready Expansion of manufacturing footprint is expected to enable increased scale and support capacity for potential partner programs RT-101 program discontinued; RT-105 and RT-110 programs paused The company will reduce... Read More

Daily administration for 60 days was well-tolerated with no treatment-related adverse events Preclinical data support the safety and tolerability of RaniPill® capsule for subsequent clinical studies SAN JOSE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs,... Read More

RaniPill ® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) RaniPill® HC has achieved a cumulative >90% success rate across multiple preclinical studies RaniPill® HC shortlisted as a finalist by Fierce Life Sciences Innovation Awards SAN JOSE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage... Read More

SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present an abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) taking place on October 13-16, 2023 in Vancouver,... Read More

Topline results from this study are expected in early Q1 2024 Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the initiation of a Phase 1... Read More

Two preclinical studies of RaniPill ® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate Rani will continue preclinical testing to confirm preliminary reliability rate and optimize device performance Increased payload of up to 20mg enables potential delivery of 90+ additional drug candidate s SAN JOSE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Rani... Read More

SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that Rani will participate in and present at two upcoming investor conferences in September 2023. These conferences include: H.C. Wainwright 25 th Annual Global Investment Conference... Read More

Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 Appointment of Kate McKinley as Chief Business Officer Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 Presentation of late-breaking abstract on oral... Read More

SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in three upcoming investor conferences in August 2023. These conferences include: BTIG Virtual Biotechnology Conference Date: Monday, August 7 th at... Read More

SAN JOSE, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced that its abstract entitled “An Orally Administered Robotic Pill (RP) Reliably and Safely Delivers the Human Parathyroid Hormone Analog hPTH (1-34) (Teriparatide) With High Bioavailability in... Read More

SAN JOSE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that a late-breaking abstract “Oral Delivery of a GLP-1 Agonist with High Bioavailability in Dogs and Humans” has been selected for poster presentation at the American Diabetes... Read More

SAN JOSE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has expanded its partnership with Celltrion by entering into an agreement for the development of RT-105, an orally administered adalimumab biosimilar. Rani’s first partnership... Read More

SAN JOSE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company’s Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 from... Read More

SAN JOSE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that three submitted abstracts were accepted for poster presentations at the 105 th annual meeting of The Endocrine Society (ENDO 2023) taking place June 15-18, 2023, in Chicago,... Read More

SAN JOSE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has appointed Kate McKinley as its Chief Business Officer. “Kate is a seasoned industry leader, and we are thrilled to welcome her to Rani’s executive team,” said Talat Imran,... Read More

Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing a biosimilar for the monoclonal antibody ustekinumab Received preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2H of 2023 SAN JOSE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Rani... Read More

SAN JOSE, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company’s Chief Executive Officer, Talat Imran, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023 at 11:30 am E.T.... Read More

SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company’s Chief Executive Officer, Talat Imran, will present at the 22 nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 12:45 p.m. PT / 3:45 p.m. ET.... Read More

Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis Received preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing an ustekinumab biosimilar Conference... Read More

SAN JOSE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2022 on Wednesday, March 22 after the close of trading. Rani’s management team will... Read More

SAN JOSE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has partnered with Celltrion for the development of RT-111, an orally administered ustekinumab biosimilar. Under a license and supply agreement, Celltrion will exclusively... Read More

Preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable Multiple anticipated clinical milestones expected in 2023, including initiation of Phase 2 study of RT-102 in osteoporosis SAN JOSE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral... Read More

RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1 Study Repeat doses of RT-102 were generally well tolerated, with no serious adverse events RaniPill™ GO delivered PTH to subjects with a 91% success rate and demonstrated high bioavailability Data from Part 1 and Part 2 of the Phase 1 study of RT-102 support advancement to a Phase 2 study Company to host conference call today at 4:30 pm ET / 1:30... Read More

Rani announces preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn’s disease and psoriasis RT-102 Phase 1 repeat-dose topline data anticipated in 4Q 2022 Initiation of in vivo studies with fully-autonomous RaniPill HC anticipated in 4Q 2022 Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”)... Read More

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company will present at the H.C. Wainwright Global Investment Conference, taking place September 12 - 14, 2022 virtually and in-person. Talat Imran, Chief Executive Officer of Rani, is scheduled to present on Monday, September... Read More

Rani Therapeutics Holdings, Inc . (“Rani Therapeutics” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has terminated the underwritten public offering of its Class A common stock previously announced on August 10, 2022. The termination results from an assessment by the Company's management that current market conditions... Read More

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today announced that it intends to offer and sell shares of its Class A common stock in an underwritten public offering (the “Offering”). Rani Therapeutics expects to grant the underwriters a 30-day option to purchase additional shares up to 15% of the aggregate number of... Read More

Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis Anticipate initiating an additional Phase 1 clinical trial in 2H 2022 Capitalized to fund operations into mid-2024 Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”, “the Company” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for... Read More

RT-102 was generally well-tolerated, with no RaniPill™-related adverse events Bioavailability of PTH delivered via the RaniPill was found to be 300-400% greater than PTH delivered via subcutaneous injection Improved RaniPill design enabled 95% drug delivery success rate Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of... Read More

Rani Therapeutics Holdings, Inc . (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today announced that it has entered into a loan agreement with Avenue Venture Opportunities Fund, L.P. (“Avenue”) for up to $45 million of funding. This financing is expected to support the continued advancement of the RaniPill platform and ongoing clinical... Read More

Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of up to 20 mg Strengthened Board with the appointment of Lisa Rometty Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the... Read More

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will present at two upcoming investor conferences in May: Bank of America 2022 Healthcare Conference. Mr. Imran will present on Tuesday, May 10 at 5:20 PM Pacific Time / 8:20 PM Eastern... Read More

The winners of Fast Company ’s 2022 World Changing Ideas Awards were announced today, with Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), earning the top honors in the Health category for its RaniPill™ capsule. Rani’s mission is to eliminate painful and inconvenient injections for patients with chronic diseases, such as osteoporosis, rheumatoid arthritis, psoriasis, and hypoparathyroidism.... Read More

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will present at the 21 st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 12:45 p.m. PT / 3:45 p.m. ET. Interested parties can access the live audio webcast for... Read More

Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis - Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of up to 20 mg - Strengthened Board with the appointments of Lyn Baranowski and Lisa Rometty – Conference call and webcast today at 4:30 p.m. ET - Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics... Read More

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company will release fourth quarter and full year 2021 financial results on Tuesday, March 29, 2022 after the close of market. Rani will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same... Read More

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the initiation of a Phase 1 study of RT-102, an oral formulation of the human parathyroid hormone analog PTH(1-34) for the treatment of osteoporosis, delivered via RaniPill™ capsule. Osteoporosis is a bone loss disease that affects approximately... Read More

Preclinical data demonstrates new RaniPill™ HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill™ capsule Up to 20mg payload has the potential to unlock more than 50 additional biologics for internal development or partnership Company announces preliminary consolidated financial results for the fourth quarter and year ended December 31, 2021 Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or... Read More

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the appointment of Lisa Rometty to its Board of Directors. Ms. Rometty brings significant global commercial leadership experience across a spectrum of start-ups to mature businesses in medical device, technology and pharmaceuticals. “In our effort... Read More

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the quarter ended September 30, 2021, and provided a corporate update. “I am pleased with the progress Rani has made since our IPO. As we build a solid foundation for being a successful public company, we are laser focused on... Read More

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the appointment of Lyn Baranowski to its Board of Directors. Ms. Baranowski is a distinguished biotechnology executive with nearly two decades of experience. “Lyn is a well-respected biotechnology... Read More

Rani Therapeutics (NASDAQ: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021, at 7:00 a.m. PT / 10:00 a.m. ET. Interested parties can access the live audio webcast for this conference from the... Read More

Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 30, 2021, at 9:00 a.m. PT / 12:00 p.m. ET. Interested parties can access the live audio webcast for this conference from the Events page in... Read More

IPO in July 2021 raised $84.3 million in gross proceeds Talat Imran Appointed Chief Executive Officer Enhanced leadership team with key management and board of directors’ appointments Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the second quarter ended June 30, 2021 and... Read More

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the appointment of Eric Groen as General Counsel. Mr. Groen has more than 25 years of experience managing legal matters in corporate and private practice. “Eric is an accomplished executive whose... Read More

SAN JOSE, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq:RANI) (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics today announced the final closing of its initial public offering of 7,666,667 shares of its Class A common stock, which includes 1,000,000 shares sold pursuant to... Read More